Determination of the Cut-off Value for Imatinib Plasma Levels Linked to Occurrence of Bone Pain in CML Patients.
Marwa S HamzaSamia A ShoumanRaafat AbdelfattahHeba S MoussaMervat M OmranPublished in: Drug design, development and therapy (2022)
Higher peak and trough plasma concentrations of imatinib are linked with the risk of the occurrence of bone pain as a side effect of imatinib. Monitoring plasma concentrations of imatinib is useful to predict the bone pain of imatinib and to support quality of life in patients with CML.
Keyphrases
- chronic myeloid leukemia
- chronic pain
- pain management
- bone mineral density
- neuropathic pain
- end stage renal disease
- risk assessment
- soft tissue
- bone loss
- ejection fraction
- chronic kidney disease
- newly diagnosed
- peritoneal dialysis
- spinal cord injury
- body composition
- spinal cord
- mass spectrometry
- molecularly imprinted
- solid phase extraction